You just read:

BerGenBio Meets First Efficacy Endpoint in Phase II Trial With Selective AXL Inhibitor BGB324 (bemcentinib) in NSCLC

News provided by

BerGenBio ASA

09 Jan, 2018, 07:29 GMT